Market Overview

Dr. Reddy's Announces the Launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg in the U.S. Market

Share:

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY,
along with its subsidiaries together referred to as "Dr. Reddy's") today
announced the launch of Esomeprazole Magnesium Delayed-Release Capsules
USP, 20 mg, an over-the-counter (OTC) therapeutic equivalent generic
version of Nexium® 24HR Capsules in the United States market
as approved by the U.S. Food and Drug Administration (USFDA).

Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, is an OTC
proton pump inhibitor used to treat frequent heartburn occurring two or
more days a week in adults*.

"This launch continues to demonstrate our deep R&D and manufacturing
capabilities to bring newer store-brand OTC medications to the market,"
says Milan Kalawadia, Vice President and Head, US OTC and Speciality Rx
businesses, Dr. Reddy's Laboratories. "We look forward to collaborating
with our customers to provide high-quality, affordable alternatives to
consumers."

The combined market of Nexium® 24HR Capsules and private
label OTC Esomeprazole Magnesium products had U.S. sales of
approximately $311 million for the most recent twelve months ending in
May 2018 according to IRI.

Dr. Reddy's Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg
is available in 14 count bottles sold in cartons of 1, 2, or 3 bottles
each. Each bottle contains a complete 14-day course of treatment. Use
only as directed.

*May take 1 to 4 days for full effect. IRI Latest 52 wks.
period ending May 2018
Nexium® is a registered trademark
of AstraZeneca AB.

OTC-002-0618

About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124,
NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company,
committed to providing affordable and innovative medicines for healthier
lives. Through its three businesses - Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy's
offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy's operates in markets across the globe. Our major markets
include – USA, India, Russia & CIS countries, and Europe. For more
information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the
management's current views and assumptions and involve known or unknown
risks and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. In addition to statements which are forward-looking by
reason of context, the words "may", "will", "should", "expects",
"plans", "intends", "anticipates", "believes", "estimates", "predicts",
"potential", or "continue" and similar expressions identify
forward-looking statements. Actual results, performance or events may
differ materially from those in such statements due to without
limitation, (i) general economic conditions such as performance of
financial markets, credit defaults , currency exchange rates , interest
rates , persistency levels and frequency / severity of insured loss
events (ii) mortality and morbidity levels and trends, (iii) changing
levels of competition and general competitive factors, (iv) changes in
laws and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization ,
including related integration issues.

The company assumes no obligation to update any information contained
herein.

View Comments and Join the Discussion!